Canaccord Genuity Maintains Intercept Pharmaceuticals (ICPT) Hold Recommendation
Fintel reports that on May 23, 2023, Canaccord Genuity maintained coverage of Intercept Pharmaceuticals (NASDAQ:ICPT) with a Hold recommendation. Analyst Price Forecast Suggests 160.70% Upside As of May 11, 2023, the average one-year price target for Intercept Pharmaceuticals is 24.84. The forecasts range from a low of 12.12 to a…
bubmagMay 23, 2023